Stents Market by Type, Material, Mode of Delivery, End-User

List of Tables

[194 Pages Report] The Stents Market size was estimated at USD 12.99 billion in 2023 and expected to reach USD 13.95 billion in 2024, at a CAGR 7.51% to reach USD 21.57 billion by 2030.

Stents are inserted into blocked passageways to open passages in the heart, such as weak or narrowed arteries providing oxygen-rich blood. Stents are made of either plastic or metal and are coated with drugs to help prevent blocked arteries from closing. Stenting technology is increasingly preferred over conventional balloon angioplasty due to the introduction of advanced DES and evolving bioresorbable scaffolds. The rising incidence of cardiovascular diseases, the expanding elderly population, and the increasing preference for minimally invasive procedures have created a need for the utilization of stents. However, the surging incidence of recalls of stent systems and the risk associated with the stents may adversely impact the market's growth. Moreover, introducing new stent designs and product approvals from regulatory authorities are expected to increase the adoption of stents by healthcare facilities.

KEY MARKET STATISTICS
Base Year [2023]	USD 12.99 billion
Estimated Year [2024]	USD 13.95 billion
Forecast Year [2030]	USD 21.57 billion
CAGR (%)	7.51%

Type: High global incidences of coronary diseases necessitating the deployment of coronary stents

Coronary stents are used in procedures to open clogged heart arteries, playing a critical role in the treatment of coronary heart diseases. These stents are preferred for their minimally invasive nature and the significant improvement in patient outcomes they offer. Bare-metal stents are made of a metal alloy and act as a scaffold to keep the coronary artery open. After the stent is placed in the artery during a procedure known as angioplasty, the artery heals around the stent, maintaining the artery in an open position. Drug-eluting stents represent an advancement in stent technology. These stents are coated with a medication that is slowly released (eluted) into the artery wall to prevent scar tissue growth and, subsequently, restenosis. DES have significantly reduced the incidences of restenosis and the need for repeat interventions, making them the preferred choice in most stenting procedures. Peripheral vascular stents serve to treat peripheral artery disease (PAD), targeting arteries outside the heart and brain. They are essential in managing blood flow obstruction in limbs and preventing amputations. With an aging population and rising PAD prevalence, the demand is growing. Prostatic stents are primarily used to provide relief from urinary obstruction caused by benign prostatic hyperplasia (BPH). Their preference stems from being a less invasive alternative to surgery for patients unable or unwilling to undergo traditional procedures. Stent grafts are used in endovascular procedures to treat abdominal and thoracic aortic aneurysms. They are preferred due to their minimally invasive approach, which reduces recovery time and risk of complications compared to open surgery. Urinary stents are employed to ensure the passage of urine in cases of obstructions in the urinary tract. They are crucial in the management of kidney stones and other urological conditions. The preference for urinary stents lies in their role in preventing or treating renal failure.

End-User: Expansion of hospitals across the world supported by government initiatives for improving healthcare infrastructure

Ambulatory surgical centers (ASCs) represent a critical setting for stent procedures, offering outpatient services that typically focus on elective surgeries. ASCs are characterized by their efficiency, cost-effectiveness, and the convenience they offer to patients. ASCs primarily deal with less complex coronary and peripheral interventions. The preference for lightweight, easy-to-deploy, and high-precision stents is essential in this environment to minimize operative and recovery time. This makes drug-eluting stents (DES) highly favored in ASCs for their reduced risk of restenosis. Cardiac centers are specialized facilities focused exclusively on the diagnosis and treatment of heart conditions. They are equipped to perform a diverse range of stent placements, including more complex procedures that require advanced infrastructural capabilities, such as hybrid operating rooms. There's a demand for versatile stenting options in these centers, including bioresorbable vascular scaffolds (BVS) and bio-engineered stents, to cater to a diverse range of coronary artery diseases. Capability in treating complex cases, such as bifurcation lesions or chronic total occlusions, is crucial. Hospitals represent the broadest end-user sector, encompassing a wide range of capabilities. The versatility of hospital services and their capacity to manage high-volume cases has grown in recent years. The preference in hospitals leans toward stents that offer a combination of efficacy, versatility, and cost-effectiveness. There is also a notable requirement for stents that support a broad range of vessel sizes and lesion types, accommodating the diverse patient demographic.

Regional Insights

The stent market in the Americas is advanced, driven by the presence of well-established and recognized manufacturers serving a diverse portfolio of stents and constantly upgrading their R&D to keep up with medical requirements. In the past few years, the U.S. Food & Drug Administration has provided multiple approvals for drug-eluting and cardiac stents, supporting further stent innovation in the region. The Asia-Pacific region is a mass provider of raw materials to Western nations and is occupied by trusted stent producers across India, China, and Japan. The country observes an improved reimbursement structure for heart surgeries and stent usage, and governments are working toward offering cost-effective stents to healthcare facilities. Europe has a more standardized stent market characterized by safety initiatives and research activities focused on introducing biodegradable stents. The Middle East region witnesses an exponential increase in investments in healthcare infrastructure advancements, creating the region a potential base for company expansion for market players.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Stents Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stents Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Stents Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alvimedica, Andramed GmbH, Arterius Limited, B. Braun SE, Balton Sp. z o. o., Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cardinal Health Inc., Cook Medical LLC, Elixir Medical Corporation, Eurocor Tech GmbH, Integer Holdings Corporation, KYOTO MEDICAL PLANNING Co., Ltd., Lepu Medical Technology(Beijing)Co., Ltd., Medtronic PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Mitra Industries Pvt. Ltd., Nano Therapeutics Pvt. Ltd., QMD, REVA Medical, LLC, Rontis AG, Scitech Medical Products SA, SLTL Group, Stryker Corporation, Terumo Corporation, Veryan Medical Ltd., and W. L. Gore & Associates, Inc..

Market Segmentation & Coverage

This research report categorizes the Stents Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Coronary Stents
  - Bare-metal Stents
  - Drug-eluting Stents

Peripheral Vascular Stents
Prostatic Stents
Stent Grafts
Urinary Stents

Material
- Biomaterials
- Metallic Stents
  - Cobalt-Chromium
  - Nickel Titanium
  - Platinum Chromium
  - Stainless Steel
Mode of Delivery
- Balloon-expandable Stents
- Self-expanding Stents

End-User
- Ambulatory Surgical Centers
- Cardiac Centers
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Stents Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stents Market?

3. What are the technology trends and regulatory frameworks in the Stents Market?

4. What is the market share of the leading vendors in the Stents Market?

5. Which modes and strategic moves are suitable for entering the Stents Market?

Product Code: MRR-434CCDA04EF3

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of cardiovascular diseases and need for improved-quality stents
  - 5.1.1.2. Growing inclination toward minimally invasive surgeries
  - 5.1.1.3. Surging preference for biodegradable and bioabsorbable stents
- 5.1.2. Restraints
  - 5.1.2.1. Surging incidence of recalls of stent systems
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging innovations in stent designs for high accuracy and reliability
  - 5.1.3.2. The surge in product approvals from regulatory authorities
- 5.1.4. Challenges
  - 5.1.4.1. Risks of the utilization of stents and associated health consequences
5.2. Market Segmentation Analysis
- 5.2.1. Type: High global incidences of coronary diseases necessitating the deployment of coronary stents
- 5.2.2. End-User: Expansion of hospitals across the world supported by government initiatives for improving healthcare infrastructure
5.3. Market Trend Analysis
- 5.3.1. Surging government approvals coupled with increased availability of stents in emerging countries of the Americas
- 5.3.2. High provision of raw materials and improved government assistance to reduce stent prices in Asia
- 5.3.3. Enhanced reimbursement policies in Europe and favorable manufacturing facility expansion in the Middle East & Africa
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Stents Market, by Type

6.1. Introduction
6.2. Coronary Stents
6.3. Peripheral Vascular Stents
6.4. Prostatic Stents
6.5. Stent Grafts
6.6. Urinary Stents

7. Stents Market, by Material

7.1. Introduction
7.2. Biomaterials
7.3. Metallic Stents

8. Stents Market, by Mode of Delivery

8.1. Introduction
8.2. Balloon-expandable Stents
8.3. Self-expanding Stents

9. Stents Market, by End-User

9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Cardiac Centers
9.4. Hospitals

10. Americas Stents Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Stents Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Stents Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Olympus to Acquire Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd.
- 13.3.2. Medtech giant Cordis acquires MedAlliance in a USD 1.1 billion deal.
- 13.3.3. Getinge partners with Medtronic for the manufacturing of the Radiant[TM] balloon-expandable covered stent.
- 13.3.4. Medtronic receives CE mark for the first balloon-expandable covered stent indicated for ChEVAR.
- 13.3.5. Medtronic launches the latest generation drug-eluting coronary stent system following CE Mark approval.
- 13.3.6. Biosensors International Wins FDA Approval For Drug-Eluting Coronary Stent.
- 13.3.7. San Diego's Reva Medical raises USD 45 M to develop naturally absorbable stents for lower legs.
- 13.3.8. Micro-Tech Endoscopy Announces Distribution Partnership with Thoracent to Bring Leading Tracheal Y-Stent System to the U.S. Market.
- 13.3.9. FDA-Approved FFRangio from CathWorks Receives USD 75 Million Investment from Medtronic with an Option for Eventual Acquisition for Over a Half a Billion.
- 13.3.10. Abbott launches Xience Skypoint drug-eluting stent in extended sizes.

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio